LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Type of COVID-19 Test Offers Advantages over Lateral Flow Tests

By LabMedica International staff writers
Posted on 14 Apr 2022
Image: Nanoparticles could enable a more sensitive rapid COVID-19 test (Photo courtesy of Newcastle University)
Image: Nanoparticles could enable a more sensitive rapid COVID-19 test (Photo courtesy of Newcastle University)

Rapid antigen tests can quickly and conveniently tell a person that they are positive for Covid-19. However, because the antibody-based tests aren’t very sensitive, they can fail to detect early infections with low viral loads. Now, a team of researchers has developed a rapid test that relies on molecularly imprinted polymer nanoparticles, rather than antibodies, for detection.

The gold standard for COVID-19 diagnosis remains the reverse transcription-polymerase chain reaction (RT-PCR). Although this test is highly sensitive and specific, it takes 1-2 days to get a result, is expensive and requires special lab equipment and trained personnel. In contrast, rapid antigen tests are fast (15-30 minutes), and people can take them at home with no training, but they lack sensitivity, sometimes resulting in false negatives. Also, the tests use antibodies against SARS-CoV-2 for detection, which can’t withstand wide ranges of temperature and pH. The research team at Newcastle University (Newcastle, Tyne and Wear, UK) wanted to make a low-cost, rapid, robust and highly sensitive COVID-19 test that uses molecularly imprinted polymer nanoparticles (nanoMIPs) instead of antibodies.

To make nanoMIPs, the researchers began by attaching a peptide from the SARS-CoV-2 spike protein to a solid support. Then, they added nanoparticle building blocks and polymerized them around the peptide, creating nanoparticles with a binding site specific for the coronavirus spike protein. They isolated the nanoparticles that bound most strongly to the peptide and attached them to a screen-printed electrode. After showing that the nanoMIPs could bind SARS-CoV-2, they added the electrode to a small 3D-printed device that measured changes in thermal resistance that occurred upon binding.

When the team added samples from seven patient nasopharyngeal swabs to the device, the liquid flowed over the electrode, and the researchers detected a change in thermal resistance for samples that had previously tested positive for COVID-19 by RT-PCR. The test required only 15 minutes, and preliminary results indicated that it could detect a 6,000-times lower amount of SARS-CoV-2 than a commercial rapid antigen test. Unlike antibodies, the nanoMIPs withstood warm temperatures - which could give the test a longer shelf life in hot climates - and acidic pH - which might make it useful for monitoring SARS-CoV-2 in wastewater. However, to prove that the test has a lower false negative rate than existing rapid antigen tests, it must be tested on many more patient samples, according to the researchers.

“We develop a new type of COVID-19 test which has many advantages over current lateral flow tests. For example, lateral flow tests use biological antibodies to trap and detect the Covid-19 virus, whereas we use a synthetic alternative known as polymer antibodies. This allows for a test which is as fast - 15 mins, and cheap as a lateral flow test but can detect 6000-times smaller amounts of the COVID-19 virus,” said Dr. Marloes Peeters, Senior Lecturer at Newcastle University’s School of Engineering. “Consequently, this will improve test accuracy, particularly for asymptomatic or pre-symptomatic individuals. Moreover, synthetic antibodies are very robust which means the tests have a longer shelf-life, can be used in hot climates with no issues and will not produce false-positive results in acidic media, such as soft drinks.”

“In the future, we hope to further validate our polymer antibody by testing more patient samples, including saliva samples and samples from the omicron variant. Additionally, the polymer antibodies can be easily adapted for any new COVID-19 variants or other emerging pathogens,” added Dr. Peeters.

Related Links:
Newcastle University 

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control

Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
PURITAN MEDICAL